OTCM
OBIMF
Market cap77mUSD
, Last price
USD
Name
Ondine Biomedical Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
19.04%
Rev. 5Y
8.17%
Div Yld LY
—
Div Yld TTM
—
Revenues
3m
+29.45%
Net income
-30m
L+54.93%
CFO
-24m
L+54.33%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
Key people
Nicolas Loebel
President, Chief Technology Officer, Executive Director · since 2017
Alan Thomas
Chief Financial Officer · since 2025
William Kanz
Senior Vice President, Engineering and Operations · since 2024
Nikita Parkhaev
Vice President - Finance · since 2024
Roger Andersen
Vice President - Regulatory and Medical Affairs · since 2021
Jason Hickok
Vice President - Clinical and Medical Affairs · since 2021
Matt Ross
Vice President - Sales and Marketing · since 2023
Angelika Vance
Vice President - Corporate Communications · since 2022
Carolyn Cross
Chief Executive Officer, Executive Director · since 2021
Chief Medical Officer · since 2024
Elaine Lei
Company Secretary · since 2024
Junaid Bajwa
Non-Executive Director · since 2021
Margaret Shaw
Non-Executive Director · since 2024
Jean Charest
Non-Executive Independent Chairman of the Board · since 2018
Jean Duvall
Senior Independent Non-Executive Director · since 2021
Headquarters & legal address
SUITE 888 - 1100 MELVILLE ST
VANCOUVER, BC V6E 4A6
CA
VANCOUVER, BC V6E 4A6
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||